LT4341B - Toninės kiaušidžių estrogeno sekrecijos sureguliavimas pailgintiems terapiniams režimams - Google Patents

Toninės kiaušidžių estrogeno sekrecijos sureguliavimas pailgintiems terapiniams režimams Download PDF

Info

Publication number: LT4341B
Authority: LT; Lithuania
Prior art keywords: dose; estrogen; gnrh; use according; antagonist
Prior art date: 1994-07-22

Application number

LT97-021A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT97021A (en

Inventor

Gary D. Hodgen

Audrey Philips

Original Assignee

The Medical College Of Hampton Roads

Orto Pharmaceutical Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-22

Filing date

1997-02-20

Publication date

1998-05-25

1997-02-20 Application filed by The Medical College Of Hampton Roads, Orto Pharmaceutical Corporation filed Critical The Medical College Of Hampton Roads

1998-02-25 Publication of LT97021A publication Critical patent/LT97021A/xx

1998-05-25 Publication of LT4341B publication Critical patent/LT4341B/lt

Links

239000000262 estrogen Substances 0.000 title claims abstract description 57
229940011871 estrogen Drugs 0.000 title claims description 55
230000028327 secretion Effects 0.000 title claims description 16
230000002611 ovarian Effects 0.000 title description 14
230000001256 tonic effect Effects 0.000 title description 7
238000011285 therapeutic regimen Methods 0.000 title description 3
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims abstract description 69
239000000186 progesterone Substances 0.000 claims abstract description 29
229960003387 progesterone Drugs 0.000 claims abstract description 29
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims abstract description 27
239000002474 gonadorelin antagonist Substances 0.000 claims abstract description 27
229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 claims abstract description 27
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims abstract description 26
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims abstract description 26
229940035638 gonadotropin-releasing hormone Drugs 0.000 claims abstract description 26
238000012360 testing method Methods 0.000 claims abstract description 23
230000000694 effects Effects 0.000 claims abstract description 20
239000005557 antagonist Substances 0.000 claims abstract description 19
239000003814 drug Substances 0.000 claims abstract description 16
238000004519 manufacturing process Methods 0.000 claims abstract description 14
230000035755 proliferation Effects 0.000 claims abstract description 14
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 36
229930182833 estradiol Natural products 0.000 claims description 36
229960005309 estradiol Drugs 0.000 claims description 31
210000002966 serum Anatomy 0.000 claims description 19
230000001419 dependent effect Effects 0.000 claims description 16
230000002357 endometrial effect Effects 0.000 claims description 15
201000009273 Endometriosis Diseases 0.000 claims description 13
239000003163 gonadal steroid hormone Substances 0.000 claims description 12
230000001965 increasing effect Effects 0.000 claims description 10
230000004044 response Effects 0.000 claims description 7
230000001225 therapeutic effect Effects 0.000 claims description 7
206010047998 Withdrawal bleed Diseases 0.000 claims description 5
230000001186 cumulative effect Effects 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 3
238000007726 management method Methods 0.000 claims description 3
208000006069 Corneal Opacity Diseases 0.000 claims 1
241001123008 Leukoma Species 0.000 claims 1
241000124008 Mammalia Species 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 26
238000000034 method Methods 0.000 abstract description 10
230000005764 inhibitory process Effects 0.000 abstract description 7
210000004291 uterus Anatomy 0.000 abstract description 3
150000003431 steroids Chemical class 0.000 abstract description 2
210000004379 membrane Anatomy 0.000 abstract 2
230000002045 lasting effect Effects 0.000 abstract 1
230000001568 sexual effect Effects 0.000 abstract 1
241000282693 Cercopithecidae Species 0.000 description 19
201000000736 Amenorrhea Diseases 0.000 description 17
206010001928 Amenorrhoea Diseases 0.000 description 17
231100000540 amenorrhea Toxicity 0.000 description 17
239000000583 progesterone congener Substances 0.000 description 16
229940079593 drug Drugs 0.000 description 11
VSZVSSYQFUFEQG-GJZGRUSLSA-N (2s)-5-amino-2-[[(2s)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-5-oxopentanoic acid Chemical compound C1=CC=CC2=CC(C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=CC=C21 VSZVSSYQFUFEQG-GJZGRUSLSA-N 0.000 description 10
108010082661 2-naphthylalanyl-glutamic acid Proteins 0.000 description 10
239000000556 agonist Substances 0.000 description 10
206010030247 Oestrogen deficiency Diseases 0.000 description 8
241000288906 Primates Species 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
208000032843 Hemorrhage Diseases 0.000 description 7
230000000740 bleeding effect Effects 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
201000010260 leiomyoma Diseases 0.000 description 7
230000007774 longterm Effects 0.000 description 7
230000002175 menstrual effect Effects 0.000 description 6
230000027758 ovulation cycle Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
108700026555 N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Arg(5)-Glu(6)-AlaNH2(10)- LHRH Proteins 0.000 description 4
206010046798 Uterine leiomyoma Diseases 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
229910052500 inorganic mineral Inorganic materials 0.000 description 4
239000011707 mineral Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000003127 radioimmunoassay Methods 0.000 description 4
238000004448 titration Methods 0.000 description 4
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
238000013459 approach Methods 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000001076 estrogenic effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 description 3
108010083551 iturelix Proteins 0.000 description 3
230000009245 menopause Effects 0.000 description 3
230000005906 menstruation Effects 0.000 description 3
230000036407 pain Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
201000007954 uterine fibroid Diseases 0.000 description 3
201000004384 Alopecia Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010065687 Bone loss Diseases 0.000 description 2
125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 description 2
102000006771 Gonadotropins Human genes 0.000 description 2
108010086677 Gonadotropins Proteins 0.000 description 2
102000008238 LHRH Receptors Human genes 0.000 description 2
108010021290 LHRH Receptors Proteins 0.000 description 2
206010027304 Menopausal symptoms Diseases 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000037182 bone density Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
-1 for example Chemical class 0.000 description 2
239000000499 gel Substances 0.000 description 2
210000004392 genitalia Anatomy 0.000 description 2
239000002622 gonadotropin Substances 0.000 description 2
230000003676 hair loss Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
238000002657 hormone replacement therapy Methods 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000011866 long-term treatment Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
239000003488 releasing hormone Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
206010006179 Breast atrophy Diseases 0.000 description 1
241000195940 Bryophyta Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010027514 Metrorrhagia Diseases 0.000 description 1
206010027951 Mood swings Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000001164 Osteoporotic Fractures Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000000450 Pelvic Pain Diseases 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
102100024028 Progonadoliberin-1 Human genes 0.000 description 1
241000220010 Rhode Species 0.000 description 1
206010039792 Seborrhoea Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
229920002253 Tannate Polymers 0.000 description 1
206010046788 Uterine haemorrhage Diseases 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000011292 agonist therapy Methods 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000001548 androgenic effect Effects 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
229940127233 azaline B Drugs 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000006071 cream Substances 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
229960000766 danazol Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
210000005168 endometrial cell Anatomy 0.000 description 1
201000006828 endometrial hyperplasia Diseases 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
230000001456 gonadotroph Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000012051 hydrophobic carrier Substances 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
238000012153 long-term therapy Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000001592 luteinising effect Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
235000011929 mousse Nutrition 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000037312 oily skin Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
230000011599 ovarian follicle development Effects 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000035946 sexual desire Effects 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229940086735 succinate Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
239000006208 topical dosage form Substances 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

LT97-021A 1994-07-22 1997-02-20 Toninės kiaušidžių estrogeno sekrecijos sureguliavimas pailgintiems terapiniams režimams LT4341B (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US27959394A	1994-07-22	1994-07-22

Publications (2)

Publication Number	Publication Date
LT97021A LT97021A (en)	1998-02-25
LT4341B true LT4341B (lt)	1998-05-25

Family

ID=23069633

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT97-021A LT4341B (lt)	1994-07-22	1997-02-20	Toninės kiaušidžių estrogeno sekrecijos sureguliavimas pailgintiems terapiniams režimams

Country Status (8)

Country	Link
US (1)	US5658884A (ar)
KR (1)	KR970704460A (ar)
JO (1)	JO1879B1 (ar)
LT (1)	LT4341B (ar)
MY (1)	MY121568A (ar)
RO (1)	RO118794B1 (ar)
UA (1)	UA51627C2 (ar)
ZA (1)	ZA956099B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6265393B1 (en)	1998-08-07	2001-07-24	Heinrichs William Leroy	Prevention of endometriosis signs or symptons
US6703367B1 (en)	1999-04-27	2004-03-09	Praecis Pharmaceuticals Inc.	Methods for treating hot flashes and gynaecomastia
US7005418B1 (en) *	1999-09-23	2006-02-28	Zentaris Gmbh	Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
AU769482B2 (en) *	1999-09-23	2004-01-29	Zentaris Gmbh	Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
CA2812438A1 (en) *	2010-10-01	2012-04-05	Indiana University Research And Technology Corporation	Treatment of symptoms associated with menopause
EP3560555A1 (en) *	2018-04-26	2019-10-30	LifeArc	A composition for treating one or more estrogen related diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5211952A (en) *	1991-04-12	1993-05-18	University Of Southern California	Contraceptive methods and formulations for use therein

1995
- 1995-06-06 US US08/467,860 patent/US5658884A/en not_active Expired - Fee Related
- 1995-07-18 UA UA97020728A patent/UA51627C2/uk unknown
- 1995-07-18 RO RO97-00117A patent/RO118794B1/ro unknown
- 1995-07-18 KR KR1019970700390A patent/KR970704460A/ko not_active Ceased
- 1995-07-21 ZA ZA9506099A patent/ZA956099B/xx unknown
- 1995-07-22 JO JO19951879A patent/JO1879B1/ar active
- 1995-07-22 MY MYPI95002106A patent/MY121568A/en unknown
1997
- 1997-02-20 LT LT97-021A patent/LT4341B/lt not_active IP Right Cessation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GORDON ET AL.: "Suppression of Ovarian Estradiol Secretion by single injection of Antide in Monkey Follicular Phase", J. CLIN. ENDOCRIN. METAB., 1991, pages 1262

Also Published As

Publication number	Publication date
US5658884A (en)	1997-08-19
LT97021A (en)	1998-02-25
ZA956099B (en)	1997-02-18
JO1879B1 (ar)	1996-07-25
UA51627C2 (uk)	2002-12-16
RO118794B1 (ro)	2003-11-28
MY121568A (en)	2006-02-28
KR970704460A (ko)	1997-09-06

Legal Events

Date

Code

Title

Description

2004-12-27

PD9A

Change of patent owner

Owner name: EASTERN VIRGINIA MEDICAL SCHOOL, US

Effective date: 20041022

Owner name: ORTO PHARMACEUTICAL CORPORATION, US